Canadian Phase Onward | Toronto, Canada
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Full description
This is a multi-center, open-label study of up to 700 participants with SHTG who would be rolled over from studies ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326). Day 1 of this study may be same as the Week 53 visit of either ISIS 678354-CS5 or ISIS 678354-CS6, as applicable. Participants will receive olezarsen during the 53-week treatment period. The study will include a 31-day qualification Period, a 53-week treatment period, and a 13-week post-treatment period.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
NOTE: Other Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
700 participants in 1 patient group
Loading...
Central trial contact
Ionis Pharmaceuticals, Inc.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal